



## TRIGEMINAL NEURALGIA- AN OVERVIEW, CHANGING TRENDS IN DIAGNOSIS & IT'S MANAGEMENT.

### Dental Science

**Dr. Rima. R. Patel\*** B.D.S., \*Corresponding Author

**Dr. Janmeet Randhawa** B.D.S.,

**Dr. Nidhi Senta** M.D.S 2<sup>ND</sup> Year P.G.,

### ABSTRACT

Trigeminal neuralgia is a peripheral neuropathy characterized by intermittent episodes of lancinating pain originating in the sensory root of the trigeminal nerve. The most commonly involved area is the mandibular division with a higher prevalence on the right side. Advances in the field of MRI have play an important role in its diagnosis, especially in case of nerve compression and/or neurovascular conflict. Primary management of trigeminal neuralgia is the use of first line drug that is carbamazepine, although some patients may require surgical or radiotherapeutic intervention, who does not respond to drug therapy. MRI serves as a powerful tool in the segmental evaluation of the trigeminal nerve. A proper diagnosis with a organized treatment protocol is critical for managing cases of trigeminal neuralgia

### KEYWORDS

Trigeminal neuralgia, fifth cranial pair, CN V3

### INTRODUCTION

Trigeminal neuralgia is the pain experienced along the branches of the trigeminal nerve. The pain is sudden and often unilateral. It commonly involved the maxilla and mandibular divisions where patients commonly describe as a recurrent, brief, and stabbing pain. It can last from a few seconds to several minutes. The pain can occur from a few to hundreds of attacks a day.<sup>[1]</sup> International Association for the Study of Pain (IASP) defines Trigeminal neuralgia (TN) as a sudden, usually unilateral, severe, brief, stabbing recurrent pain in the distribution of one or more branches of the fifth cranial nerve.<sup>[2]</sup>

### Anatomy

The trigeminal nerve is the fifth cranial pair (CN V) consisting of a large sensory root and small motor root. The sensory root transmits sensory information from the unilateral hemiside and is divided into three ophthalmic (V1), maxillary (V2), and mandibular (V3). The motor root innervates the unilateral masticator muscles. In MRI motor root can't be distinguished from the sensory root. It has a common extracranial pathway with the common trunk of the nerve and root of CN V3 over the whole pathway.<sup>[3]</sup>

The gasserian ganglion is located in the trigeminal fossa (Meckel cave) of the petrous bone in the middle cranial fossa. It contains the first-order general somatic sensory fibers that carry pain, temperature, and touch. The peripheral processes of neurons in the ganglion form the 3 divisions of the trigeminal nerve (i.e. ophthalmic, maxillary, and mandibular). The ophthalmic division exits the cranium via the superior orbital fissure; the maxillary divisions exit via the foramen rotundum and mandibular divisions exit via foramen ovale.

Trigeminal nerve mainly mediate the majority of nociceptive impulses from the orofacial region. The action potentials are transmitted from its peripheral branches, ophthalmic (V1), maxillary (V2), and mandibular (V3), by pseudo-unipolar neurons with the cell bodies located in the trigeminal (gasserian or semilunar) ganglion.<sup>[4]</sup>

### Types of Trigeminal Neuralgia

1. Possible Trigeminal Neuralgia
  - paroxysmal nature
  - Continuous pain may exist
  - Not triggered by external mechanical stimuli
2. Classical Trigeminal Neuralgia
  - attacks are paroxysmal and triggered by mechanical stimuli
  - diagnosis confirmed by MRI. (most common cause is neurovascular compression)
3. Idiopathic Trigeminal Neuralgia
  - May be triggered by extraneous stimuli
  - MRI does not show any neurovascular compression,
  - associate with cerebellopontine angle lesions

### Clinical Characteristic

Trigeminal neuralgia typically manifests as a sudden, unilateral,

intermittent paroxysmal, sharp, shooting, lancinating, shock like pain, elicited by slight touching superficial "trigger points" which radiates from that point, across the distribution of one or more branches of the trigeminal nerve. Pain is rarely bilateral (1–4%). Episodes of severe shooting pain that may feel like an electric shock.

Pain is usually confined to one part of one division of trigeminal nerve—mandibular or maxillary, but may occasionally spread to an adjacent division or rarely involve all three divisions.

Pain rarely crosses the midline: The pain is of short duration and lasts for a few seconds to 2 minutes, but may recur with variable frequency. Even though there is a refractory period (complete lack of pain) between the attacks. The paroxysms occur in cycles, each cycle lasting for weeks or months and with time, the cycle appears closer and closer.<sup>[5]</sup>

Classical features: Presence of trigger points (intraoral or extraoral). These triggers points can be stimulated while Eating, Drinking, Smiling, Brushing your teeth, Talking, Touching your face, Washing your face, shaving.

The location of the trigger points depends on which division of trigeminal nerve is involved.

- In V1 —the trigger zone usually lies over the supraorbital ridge of the affected side.
- In V2 —points are located on the skin of the upper lip, ala of nose or cheek or on the upper gums.
- In V3 —this is the most frequently involved branch
- Trigger points are seen over the lower lip, teeth or gums of the lower jaw. Usually tongue is not involved.<sup>[6,7]</sup>

### Diagnosis

Trigeminal neuralgia usually has a characteristic clinical feature. There is a sudden and severe lancinating pain, usually unilateral, aggravated by gently touching triggers points. This pain occurs within the trigeminal nerve distribution; typically involving the maxillary nerve (V2) or mandibular nerve (V3) distribution.<sup>[8]</sup>

Pain symptoms may be:<sup>[9]</sup>

- Dysaesthesia (abnormal perception of pain)
- Allodynia (due to a stimulus which does not normally provoke pain)
- Hyperalgesia (an increased sensitivity to pain) In some patients, these painful bursts can be triggered simply by cutaneous contact with a trigger zone or during movement. Where this trigger zone exists, there is a refractory period at the end of an episode of pain during which the subject can touch the trigger zone without causing pain. Neurological examination of these patients is usually normal. Pain is relieved by sodium channels blockers. Neurovascular compression is the principal cause of trigeminal neuralgia can be ruled out by MRI.<sup>[1]</sup>

## Management

The pharmacological treatment for trigeminal neuralgia includes muscle relaxants, anticonvulsant, and neuroleptic drugs. However, the gold standard method of trigeminal neuralgia treatment is using carbamazepine.<sup>[10]</sup> Patients who do not respond to these drugs, other techniques are employed such as microvascular decompression, Gasserian ganglion percutaneous techniques, and gamma knife surgery. Both massage and needling (in the form of acupuncture) are commonly used as an alternative treatment to reduce pain in patients who suffered from trigeminal neuralgia.

Carbamazepine (anticonvulsant drug) is the drug of choice in Treatment of trigeminal neuralgia. The second drug of choice is oxcarbazepine (Better tolerability than carbamazepine) (10). Other drugs such as baclofen, lamotrigine, clonazepam, topiramate, phenytoin, gabapentin, pregabalin, and sodium valproate can be used. Polytherapy is useful when patients are unable to tolerate higher doses of carbamazepine.<sup>[11]</sup> Opioids are not prescribed as it is ineffective against trigeminal neuralgia. A multidisciplinary approach using antidepressants and anti-anxiety drugs such as amitriptyline and duloxetine is required for emotional imbalance. Acupuncture can be an option in the treatment of idiopathic trigeminal neuralgia and secondary myofascial pain associated with it.<sup>[12]</sup> Peripheral nerve blocks using local anesthetic along with absolute alcohol or glycerol is also very effective in reducing pain.<sup>[11,13]</sup> If nerve blocks are administered appropriately, patient may feel asymptomatic for months to years and may also reduce the number and doses of drugs. Many studies have shown that botulinum toxin type A (BTX-A) injections may reduce pain in people who are not relieved by medications.<sup>[14]</sup>

Surgery is normally recommended only after drugs has proved ineffective and side effects of drugs are unbearable.

Microvascular decompression is surgical treatment of choice in of trigeminal neuralgia. resistant to medical management, particularly, in young individuals.<sup>[15]</sup> Patients with significant medical comorbidities are generally advised to undergo gamma knife radiosurgery, percutaneous balloon compression, glycerol rhizotomy, and radiofrequency thermocoagulation procedures.<sup>[16]</sup>

## Percutaneous Injections

- 2 days – 1-week Interval
- Chemical Used: Local Anesthesia/ Absolute Alcohol/ Phenol glycerin mixture.
- Injection Site: Peripheral Nerve/ Trigger Zones/ Gasserian Ganglion
- Intravenous infusion of a combination of magnesium and lidocaine can be very effective in some patients.
- 5% lidocaine plaster and 8% capsaicin patch.
- Botulinum toxin Type A injections can be used as alternative treatment in patients who are not responding to drug.
- Tetracaine nerve block as an additional treatment after carbamazepine, acupuncture and peripheral nerve stimulation.

## Surgical Treatment

### Peripheral Procedures

- Peripheral injections (Local anaesthesia / absolute alcohol)
- Peripheral neurectomy
- Cryotherapy
- Gasserian ganglion procedures (glycerol /thermocoagulation/ percutaneous balloon compression)

### Intracranial Procedures

- microvascular decompression
- trigeminal root resection

## Recent Advances in Treatment Modalities

The continuous search for new drugs have led to the advancement of few drugs that reduces the electrical activity of the already excited nerve.

Vixotrigine is a novel sodium channel blocker that suppresses seizures or noxious stimuli. In a study, vixotrigine 150 mg administered thrice daily in patients with trigeminal neuralgia was compared with placebo and showed successful pain relief in the final week of therapy.<sup>22</sup> The drug was administered for 21 days. There was a reduction in the number of paroxysms by 60% compared with only 12% in placebo, and pain severity decreased by 55% compared with placebo. No serious adverse event was noted.<sup>[17]</sup>

Eslicarbazepine is a third-generation antiepileptic drug. The drug targets the voltage-gated sodium channels and is currently approved as adjunct therapy for focal seizures. In a recent open-labeled trial, 200 to 1200 mg/day eslicarbazepine was administered in a patient suffering from trigeminal neuralgia. About 88.9% patients relieved from Pain, but there was high incidence of side effects to the tune of 71%.<sup>[18]</sup>

Two randomized controlled trials tested the effectiveness of 3 mg sumatriptan subcutaneous injection and 50 mg twice daily orally. Baseline pain scores decreased 15 minutes after injection of sumatriptan.<sup>[19]</sup> Dizziness and rebound headaches are the main side effect. Sumatriptan is a 5-hydroxytyptamine receptor receptor blocker agonist. It has been extensively used in migraine and cluster headaches with good pain relief efficacy. This drug effectively inhibits vasodilation and demyelination near the inflamed trigeminal nerve root.

In hyperactive neurons CO<sub>2</sub> considered as a pain modulator. Recent studies have shown that CO<sub>2</sub> is a nociceptive modulator of afferent active trigeminal neurons as it causes a decreased mucosal pH.<sup>[20]</sup>

Usually, in patients with continuous pain mediated by other pathophysiological mechanisms, a monotherapy with sodium channel blocker is ineffective and other drugs are usually required to control the pain. Calcium channel blockers and antidepressants have been advocated in the treatment of trigeminal neuralgia in patients not relieved by monotherapy with sodium channel blockers.<sup>[21]</sup>

## Recent Advances in Nonpharmacological Therapy

Pulsed radiofrequency uses brief pulses of higher frequency alternate current to produce the same voltage or even higher fluctuations than during conventional radiofrequency (RF) treatment. Ozone injection around gasserian ganglion (OIAGG).

Few modifications have been advocated to overcome the shortcomings of conventional cryotherapy in which pain was not subsided and recurrence of pain.

These include (a) the use of a curved cryoprobe, (b) maintaining optimal temperature and pressure throughout the surgical procedure, (c) scoring of the epineurium, (d) application of petroleum jelly around the nerve before the introduction of the cryoprobe, and (e) delivery of three cycles of 3-minute freezing and 5-minute thawing to each nerve.<sup>[22]</sup>

Carbon dioxide laser is used to ablate the peripheral nerve in patients with drug refractory trigeminal neuralgia. It reduce the pain scores and persistence of pain relief till 12 months.<sup>[23]</sup>

## CONCLUSION

For accurate management, a stepwise diagnostic and treatment approach is recommended. In most cases the diagnosis can be made clinically, but routine imaging like MRI may be considered. First-line therapy for the treatment of trigeminal neuralgia is Carbamazepine (600/1200 mg/day) or Oxcarbazepine (600/1800 mg/day), switching to or adding-on lamotrigine (200/400 mg/day), pregabalin (150/600 mg/day), gabapentin (1800/4200 mg/day) or topiramate (100/400 mg/day) may also be considered. If the combination therapy fails, a switch to muscle relaxant (baclofen 40-80 mg/day) can be tried. If sufficient and compliant drug therapy failed, Surgical management should be advocated. Some intervention like Gasserian ganglion injections, gamma knife surgery, microvascular decompression should be discussed with the patients with regards to their own individual wishes and overall medical condition. New drugs, such as BTXA, may be offered to patients before surgery or to patients unwilling to undergo surgery. More studies with long-term follow-up will be required to determine the optimal timing for surgical intervention.

## REFERENCES

1. Zakrzewska JM, Linskey ME. Trigeminal neuralgia. *BMJ Clin Evid*. 2014 Oct 6;2014. pii: 1207. Review.
2. Merskey H, Bogduk N. Classification of chronic pain. Descriptors of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press, 1994.
3. D. Leclercq, J.B Thiebaud, F. Heran. Trigeminal neuralgia. *Diagn Interv Imaging* Vol 94 Issue 10 October 2013, Pages 993–1001.
4. Anisha.A.Mahtani Review on Trigeminal Neuralgia, *J. Pharm. Sci. & Res. Vol.* 8(6), 2016, 570-574.
5. Bayer DB, Stenger TG. Trigeminal neuralgia: an overview. *Oral Surg Oral Med Oral Pathol*. 1979;48:393-9.
6. Canavero S, Bonicalzi V. Drug therapy of trigeminal neuralgia. *Expert Rev Neurother*. 2006;6:429-40.
7. Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, et al. Trigeminal

- neuralgia: New classification and diagnostic grading for practice and research. *Neurology*. 2016;87(2):220-228.
8. Bennetto L, Patel NK, Fuller G. Trigeminal neuralgia and its management. *BMJ*. 2007;334:201
  9. Kumar S, Rastogi S, Kumar S, Mahendra P, Bansal M, Chandra L. Pain in trigeminal neuralgia: neurophysiology and measurement: a comprehensive review. *Journal of Medicine and Life*. 2013;6(4):383-388.
  10. Montano N, Conforti G, Di Bonaventura R, Meglio M, Fernandez E, Papacci F. Advances in diagnosis and treatment of trigeminal neuralgia. *Ther Clin Risk Manag* 2015;11:289-299.
  11. Hasan S. Trigeminal neuralgia: an overview of literature with emphasis on medical management. *Int Res J Pharma*. 2012;3:235-238.
  12. Mishra RK, Rath GP. Complimentary medicine in trigeminal neuralgia. In: Rath GP, ed. *Handbook of Trigeminal Neuralgia*. Singapore: Springer Nature; 2019; 207-213
  13. Perloff MD, Chung JS. Urgent care peripheral nerve blocks for refractory trigeminal neuralgia. *Am J Emerg Med* 2018;36(11):2058-2060.
  14. Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. *J Headache Pain* 2014;15:65-75. Gu W, Zhao W. Microvascular decompression for recurrent trigeminal neuralgia. *J Clin Neurosci* 2014;21(9):1549-1553.
  16. Abhinav K, Love S, Kalantzis G, Coakham HB, Patel NK. Clinicopathological review of patients with and without multiple sclerosis treated by partial sensory rhizotomy for medically refractory trigeminal neuralgia: a 12-year retrospective study. *Clin Neurol Neurosurg* 2012;114(4):361-365.
  17. Obermann M. Recent advances in understanding/managing trigeminal neuralgia. *F1000 Res* 2019;8:F1000
  18. Sanchez-Larsen A, Sopolana D, Diaz-Maroto I, et al. Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia. *Eur J Pain* 2018;22(6):1080-1087.
  19. Moore D, Chong MS, Shetty A, Zakrzewska JM. A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia. *Br J Anaesth* 2019;123(2):e385-e396.
  20. Vause C, Bowen E, Spierings E, Durham P. Effect of carbon dioxide on calcitonin gene-related peptide secretion from trigeminal neurons. *Headache* 2007;47(10):1385-139.
  21. Patel R, Montagut-Bordas C, Dickenson AH. Calcium channel modulation as a target in chronic pain control. *Br J Pharmacol* 2018;175(12):2173-2184.
  22. Zhou L, Shao Z, Ou S. Cryoanalgesia: electrophysiology at different temperatures. *Cryobiology* 2003;46(1):26-32.
  23. Sessirisombat S. Carbon-dioxide laser in the treatment of trigeminal neuralgia: a preliminary study. *J Interdiscipl Med Dent Sci* 2017;5:208.